Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 11 1 2016 12 29 43 48 EN Mehrdad Payandeh Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran Masoud Sadeghi Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran. AND Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran Edris Sadeghi Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran. AND Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran Alireza Janbakhsh Department of Infectious Diseases and Tropical Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran 2015 12 13 2015 12 17 Background: In developed or developing countries, the most common cancer in women is breast cancer with a pick in 40–50 years in Asia. Herein, we compared the association between IHC with FISH in HER2-positive breast cancer patients and affection of trastuzumab on disease free survival and overall survival (OS). Subjects and Methods: Immunohistochemical (IHC) analysis of hormone receptors and HER2 was performed in 133 patients with breast cancer between 2003 and 2014. Patients were selected for Herceptin adjuvant treatment, according to IHC 3+ or FISH+. The specimens for pathology reports were fixed at 10% neutral-buffered formalin (pH=7.4) for 24 hours, then sliced into 4 μm sections. Results: The mean age of patients at diagnosis was 46.39 years (range, 24-78 years), 100% female. Concordance rates between IHC and FISH were 31.1% for IHC 2+ and 84.1% for IHC 3+ (p<0.001). The 87 patients had age ≤50 years and 46 patients had >50 years. Of the 133 patients, 30 patients (22.6%) had metastasis and 72 (54.1%) had right involvement. Ninety three (69.9%) patients had lymph node invasion. 48 patients (36.1%) were treated with trastuzumab and 85 (63.9%) were treated without trsastuzumab. The 10-year survival rate was 70% and the mean survival was 49 months. Conclusions: We recommend clinicians that FISH analysis is as a predictor in breast cancer patients with IHC score 2+. In contrast, FISH analysis of IHC 3+ samples was no useful. Trastuzumab therapy is effective and tolerated for breast cancer with IHC 3+ and probably IHC 2+/FISH+. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/534 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/534/534